慢性肾脏病合并心力衰竭的个体化管理
慢性肾脏病(CKD)在心力衰竭(HF)患者中常见,占49%,与较高死亡风险比相关[2.34(95%CI 2.20-2.50);P<0.001]。HF合并CKD的管理因药物导致电解质和肌酐变化、利尿剂抵抗及器械治疗相关感染而具有挑战性。针对HFrEF合并CKD 3期患者,ACEi和MRA治疗有随机对照试验证据支持改善死亡率和HF住院,但透析患者证据不足。SGLT2抑制剂等新药在CKD 1-3期HFrEF患者中显示获益,但排除了CKD 4-5期患者。多学科个体化管理与更好护理和患者满意度相关。
要点
- CKD在HF患者中占49%,与死亡风险比2.34(95%CI 2.20-2.50;P<0.001)相关。
- HFrEF合并CKD 3期患者可从ACEi和MRA治疗中获益,但透析患者证据不足。
- SGLT2抑制剂在HFrEF合并CKD 1-3期患者中显示获益,但排除了CKD 4-5期患者。
核心结论
- HF合并CKD患者管理需个体化,多学科方法可改善护理和满意度。
研究设计与样本
- 综述性文章,总结HF合并CKD管理的现有证据。
主要发现
- CKD在HF患者中占49%,与死亡风险比2.34(95%CI 2.20-2.50;P<0.001)和多次住院相关。
- HFrEF合并CKD 3期患者中,ACEi和MRA治疗有随机对照试验证据支持改善死亡率和HF住院。
- SGLT2抑制剂在HFrEF合并CKD 1-3期患者中显示改善心血管死亡和HF住院,但排除了CKD 4-5期患者。
- β受体阻滞剂在CKD 1-3期和血液透析患者中分别有证据支持。
- 心脏再同步化治疗在CKD 1-3期患者中减少HF住院和死亡率,但在CKD 4-5期或透析患者中未显示获益。
关键数值与推荐
- CKD在HF患者中占49%,死亡风险比2.34(95%CI 2.20-2.50;P<0.001)。
- HFrEF合并CKD 3期患者中,ACEi和MRA治疗有随机对照试验证据支持改善死亡率和HF住院。
- SGLT2抑制剂在HFrEF合并CKD 1-3期患者中显示改善心血管死亡和HF住院,但排除了CKD 4-5期患者。
- 心脏再同步化治疗在CKD 1-3期患者中减少HF住院和死亡率,但在CKD 4-5期或透析患者中未显示获益。
- ICD在HFrEF合并CKD 3期患者中有益,但在透析患者中与高感染率相关。
临床怎么用
- 对HF合并CKD患者应个体化管理,考虑药物对电解质和肾功能的影响。
- HFrEF合并CKD 3期患者可考虑ACEi和MRA治疗,但需监测高钾血症风险。
- HFrEF合并CKD 1-3期患者可考虑SGLT2抑制剂,但CKD 4-5期患者证据不足。
- 透析患者使用ICD需警惕高感染率。
- 多学科个体化管理可改善护理和患者满意度。
局限性
- 许多药物试验排除了CKD 4-5期和透析患者,证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease (CKD) in heart failure (HF) patients is common, present in 49%, and is associated with a higher mortality hazard ratio [2.34 (95% confidence interval 2.20-2.50); P < 0.001] and multiple hospital admissions. The management of HF in CKD can be challenging due to drug-induced electrolyte and creatinine changes, resistance to diuretics and infections related to device therapy. Evidence for improvement in mortality and HF hospitalizations exists in HF with reduced ejection fraction (HFrEF) in Stage 3 CKD patients from randomized controlled trials of angiotensin-converting enzyme inhibitor (ACEi) and mineralocorticoid receptor antagonist therapy but not in dialysis patients, where higher doses can cause hyperkalaemia. Evidence of improvement in cardiovascular death and HF hospitalizations has emerged with the angiotensin receptor neprilysin inhibitor ivabradine and more recently with sodium-glucose cotransporter inhibitors in HFrEF patients with CKD Stages 1-3. However, these studies have excluded CKD Stages 4 and 5 patients. Evidence for β-blocker therapy exists in CKD Stages 1-3 and separately in haemodialysis patients. Cardiac resynchronization therapy reduces HF hospitalizations and mortality in patients with CKD Stages 1-3 but has not been shown to do so in CKD Stages 4 and 5 or dialysis patients. Internal cardioverter and defibrillator therapy in HFrEF patients has been shown to be beneficial in CKD 3 patients but not in dialysis patients, where it is associated with high rates of infection. For HFpEF patients with CKD, therapy is symptomatic, as there is no proven therapy for improvement in survival or hospitalizations. HF patients with end-stage kidney disease with fluid overload may benefit from peritoneal dialysis. A multidisciplinary, personalized approach has been associated with better care and improved patient satisfaction.
引用
- Banerjee D, Wang AY. Personalizing heart failure management in chronic kidney disease patients. Nephrol Dial Transplant. 2022. PMID: 33591313. doi:10.1093/ndt/gfab026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。